Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
- Ahuja, S D
- Ashkin, D
- Avendano, M
- Banerjee, R
- Bauer, M
- Bayona, J N
- Becerra, M C
- Benedetti, A
- Burgos, M
- Centis, R
- Chan, E D
- Chiang, C-Y
- Cox, H
- D'Ambrosio, L
- DeRiemer, K
- Dung, N H
- Enarson, D
- Falzon, D
- Flanagan, K
- Flood, J
- Garcia-Garcia, M L
- Gandhi, N
- Granich, R M
- Hollm-Delgado, M G
- Holtz, T H
- Iseman, M D
- Jarlsberg, L G
- Keshavjee, S
- Kim, H-R
- Koh, W-J
- Lancaster, J
- Lange, C
- de Lange, W C M
- Leimane, V
- Leung, C C
- Li, J
- Menzies, D
- Migliori, G B
- Mishustin, S P
- Mitnick, C D
- Narita, M
- O'Riordan, P
- Pai, M
- Palmero, D
- Park, S-k
- Pasvol, G
- Peña, J
- Pérez-Guzmán, C
- Quelapio, M I D
- Ponce-de-Leon, A
- Riekstina, V
- Robert, J
- Royce, S
- Schaaf, H S
- Seung, K J
- Shah, L
- Shim, T S
- Shin, S S
- Shiraishi, Y
- Sifuentes-Osornio, J
- Sotgiu, G
- Strand, M J
- Tabarsi, P
- Tupasi, T E
- van Altena, R
- Van der Walt, M
- Van der Werf, T S
- Vargas, M H
- Viiklepp, P
- Westenhouse, J
- Yew, W W
- Yim, J-J
Publication date
August 2012
DOI ISSN
1549-1676 Journal
issn:1549-1676 Language
English Citation count (estimate)
255Abstract
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB
Add to ORKG